Mednet Logo
HomePediatric Hematology/OncologyQuestion

What are your top takeaways from ISTH 2025?

1
2 Answers
Mednet Member
Mednet Member
Hematology · University of Rochester School of Medicine and Dentistry
  1. MAYARI trial - this trial was a single-arm trial for "non-severe" iTTP (excluding patients with significant cardiac or neurologic involvement) where PLEX was only used as a rescue therapy. Patients were started on caplacizumab and immunosuppression with steroids and rituximab. A large number of pa...

Register or Sign In to see full answer

What are your top takeaways from ISTH 2025? | Mednet